Effective measures for controlling trypanosomiasis

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 15, 2005, Pages 2645-2653

  Nok, Andrew J ^a  

^a AHMADU BELLO UNIVERSITY   (Nigeria)

Author keywords

Arsenicals; Eflornithine; Isometamidium; Nifurtimox; Sleeping sickness; Suramin; Trypanosomiasis

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; ADANSONIA DIGITATA EXTRACT; AFZELIA AFRICANA EXTRACT; ANTITRYPANOSOMAL AGENT; ARSENIC DERIVATIVE; ARSENOSOBENZENE; AZANTHRAQUININE; BOWELLIA DALZIELLI EXTRACT; CISSUS POPULNEA EXTRACT; DIMERCAPROL; DIMINAZENE ACETURATE; EFLORNITHINE; IMIDAZOLINE RECEPTOR; ISOMETAMIDIUM CHLORIDE; KHAYA SENEGALENSIS EXTRACT; LAWSONIA INERMIS EXTRACT; MELAMINE; MELARSEN; MELARSENOXIDE; MELARSOPROL; NIFURTIMOX; ORGANOARSENIC DERIVATIVE; PENTAMIDINE; PLANT EXTRACT; PSEUDOCEDRELA KOTSCHI EXTRACT; SURAMIN; TERMINALIA AVICENNOIDES EXTRACT; THIOL GROUP; TRYPANOTHIONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; AFRICA; AFRICAN TRYPANOSOMIASIS; AFZELIA AFRICANA; ALBIZIA GUMMIFERA; ANIMAL PARASITOSIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; BODY WEIGHT DISORDER; BOWELLIA DALZIELLI; BRAIN DISEASE; CARDIOTOXICITY; CISSUS; CISSUS POPULNEA; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DISEASE CARRIER; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EHRETIA AMOENA; ENANTIA POLYCARPA; ENTADA ABYSSINICA; GARLIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; KHAYA SENEGALENSIS; LAWSONIA INERMIS; LIVER TOXICITY; MEDICINAL PLANT; MINIMUM INHIBITORY CONCENTRATION; MITRACARPUS SCABER; NAUSEA; NEPHROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PROSTATE CANCER; PSEUDOCEDRELA KOTSCHI; PSYCHOSIS; REVIEW; SECURINEGA VIROSA; SEIZURE; SKIN MANIFESTATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TERMINALIA; TERMINALIA AVICENNOIDES; THORAX PAIN; TREATMENT FAILURE; TREATMENT OUTCOME; TREMOR; TRYPANOSOMA GAMBIENSE; TRYPANOSOMA RHODESIENSE; TSETSE FLY; VECTOR CONTROL; VERNONIA SUBULIGERA; VOMITING; WEIGHT REDUCTION;

ANIMALS; CATTLE; COMMUNICABLE DISEASE CONTROL; HUMANS; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 29244478308     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.15.2645     Document Type: Review

References (74)

1. MOLYNEUX DH: Current public health status of trypanosomiasis and Leishmaniasis. In: Trypanosomiasis and leishmaniasis: biology and control. G Hide, JC Mottram, GH Coombs, DH Holmes (Eds), CAB International, Oxon, UK (1997):39-50.
2. KRISTJANSON PM, SWALLOW BM, ROWLAND GJ et al.: Measuring the costs of African animal trypanosomiasis, the potential benefits of control and returns and research. Agr. Sys. (1999) 59:79-98.
3. CROFT SL: The current status of antiparasitic chemotherapy. Parasitology (1997) 114:S3-S25.
4. ROSS CA, SUTHERLAND DV: Drug resistance in trypanosomatids. In: Trypanosomiasis and leishmaniasis: biology and control. G Hide, JC Mottram, GH Coombs, DH Holmes (Eds), CAB International, Oxon, UK (1997):259-269.
5. BARRET MP: The fall and rise of sleeping sickness. Lancet (1999) 353:1113-1114.
6. WILLIAMSON M, CALLEUS M, KUNZT D et al.: Synthesis and activity of inhibitors highly specific for glycolytic enzymes from T. brucei. Mol. Biochem. Parasitol. (1993) 59:201-210.
7. HUNTER WN: A structure based approach to drug discovery; crystallography and implications for the development of antiparasitic drugs. Parasitology (1997) 114:S17-S29.
8. WANG CC: Validating targets for antiparasitic chemotherapy. Parasitology (1997) 114:S31-S44.
9. DENISE H, BARRET MP: Uptake and mode of action of drugs used against sleeping sickness. Biochem. Pharmacol. (2001) 61:1-5.
10. PEPIN J, MILORD F: The treatment of human African trypanosomiasis. Adv. Parasitology (1994) 33:1-47.
11. KEISER J, ERICSSON O, BURRI C: Investigations of the metabolites of the trypanocidal drug melarsoprol. Clin. Pharm. Terap. (2000) 67:478-488.
12. HARDER A, GREIF G, HABERKORN A: Chemotherapeutic approaches to protozoa: kinetoplastida- current knowledge and outlook. Parasitology Res. (2000) 87:778-780.
13. ERICSSON O, SCHWEDA E, BRONNER V et al.: Determination of melarsoprol in biological fluids by high performance liquid chromatography and characterization of stereoisomers by nuclear magnetic resonance spectroscopy. J. Chrom. B. Biomed. Sci. App. (1997) 690:243-251.
14. SCHMID C, NKUNKU S, MEROLLE A et al.: Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet (2004) 364(9436):789-790.
15. BOUTEILLE B, OUKEM O, BISSER S et al.: Treatment perspectives for human African trypanosomiasis. Fundamentals Clin. Pharmacol. (200) 17:171-181.
16. BARRETT MP: Problems for the chemotherapy of human African trypanosomiasis. Curr. Opin. Infect. Dis. (2000) 13:647-651.
17. NKANGA NG, MUTOMBO L, KAZIDI K et al.: Neuropathies arsenicals après traitement de la trypanosomiase humaine an melarsoprol. Med. Afr. Noire (1988) 35:73-76
18. BLUM J, NKUNKU S, BURRI C: Clinical description of encephalopathic syndrome and risk factors for their occurrence and outcome durin melarsoprol treatment of human African trypanosormasis. Trop. Med. Int. Health (2001) 6:390-400.
19. APTED FI: Four years experience of melarsen oxide/BAL in the treatment of late stage Rhodesian sleeping sickness. Trans. R. Soc. Trop. Med. Hyg. (1957):75-86.
20. BURRI C, KEISER J: Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop. Med. Int. Health (2001) 6:412-420.
21. LEGROS D, EVANS S, MAISO F et al.: Risk factors for the treatment failures after melarsoprol for T. b. gambiense trypanosomiasis in Uganda. Tran. Roy. Soc. Trop. Med. Hyg. (1999) 93:439-442.
22. BURRI C, NKUNKU S, MEROLLE A et al.: Efficacy of a new, concise schedule for melarsoprol in treatment of sleeping sickness caused by T. b. gambiense: a randomised trial. Lancet (2000) 355:1419-1425.
23. MATOVU E, ENYARU JC, SCHMID C et al.: Melarsoprol refractory Tb. gambiense from Omugo, north western Uganda. Trop. Med. Int. Health (2001) 6:411-497.
24. CATER NS, FAIRLAMB AH: Arsenical resistant trypanosome lack the unusual adenosine transporter. Nature (1993) 361:173-175.
25. BARRET MP, FAIRLAMB AH: The biochemical basis of arsenical-diamidine cross resistance in African trypanosomes. Parasitol. Today (1999) 15:136-140.
26. SANDS M, KRON MA, BROWN RB: Pentamidine, a review. Rev. Inf. Dis (1985) 7:625-634.
27. DAMPER D, PATTON CL: Pentamidine transport and sensitivity in brucei group trypanosomes. J. Protozool. (1976) 23:349-356.
28. CATER NS, BERGER BJ, FAIRLAMB AH: Uptake of diaimine drugs by the P2 nucleoside transporter in melarsen sensitive and resistant T. brucei. J. Biol. Chem. (1995). 270:28153-28157.
29. SCOTT AG, TAIT A, TURNER CM: T. brucei lack of cross-resistance to melarsoprol in vitro by Cymelarsen-resistant parasites. Exp. Parasitol. (1996) 86:181-190.
30. NUN CM, NEIDE S: Sequence dependent drug binding to the minor groove of DNA crystal structure of DNA dodecamer d(cgcaaatttgcg)2 complexed with propamidine. J. Med. Chem. (1995) 38:2317-2325.
31. SHAPIRO TA: Inhibition of topoisomerases in African trypanosomes. Acta Trop. (1993) 54:251-260.
32. BITONTI AJ, DUMONT JA, McCANN PP: Characterization of T. b. brucei S-adenosyl methionine decarboxylase and its inhibition by berenil, pentamidine, methylglyoxal (bis guynylhydrazone). Biochem. J. (1986) 237:685-689.
33. WOOD DH, HALL JE, ROSE BG et al.: 1,5-Bis-(amidinophenoxypentane) pentamidine is a potent inhibitor of H3-diazoxan binding to imidazole I2 binding sites. Eur. J. Pharmacol. (1998) 353:97-103.
34. HAWKING F: Concentration of Bayer 205 (Germanin) in human blood and cerebrospinal fluid after treatment. Trans. R. Soc. Trop. Med. Hyg. (1940) 34:37-52.
35. COLLINS JM, KLECKER RW, YARCHOAN R et al.: Clinical pharmacokinetics of suramin inpatients with HTLV-III/LAV infection. J. Clin. Pharm. (1986) 26:22-26.
36. VANSTERKENURG EL, COPPENS I, WILTING J et al.: The uptake of trypanocidal drug suramin in combination with LDL by T. brucei and its possible mode of action. Acta Trop. (1993) 54:237-250.
37. MAHLEY RW, INNERARITY TL, PITAS RE et al.: Inhibition of the lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in B apoproteins. J. Biol. Chem. (1977) 252:7279-7287.
38. HAWKING F. Suramin with special reference to onchocerciasis. Adv. Pharmacol. Chemother. (1978) 15:289-322.
39. WILLIAMSON J: Review of chemotherapeutic agents. In: The African trypanosomioases. HW Mulligan (Ed.), George Allen and Unwin, London, UK (1970):125-221.
40. DIXON H, GINGER CD, WILLAIMSON J: The lipid metabolism of blood and culture forms of T. lewisi and T. rhodesiense. Comp. Biochem. Physiol. (1971) 39B:247-266.
41. DE KONING HD: Transporters in African trypanosomes: role in drug action and resistance. Int. J. Parasitol. (2001) 31:512-522.
42. SCOTT AG, TAIT A, TURNER CM: Characterization of cloned lines of T. brucei expressing stable resistance to MelCy and suramin. Acta Trop. (1996) 60:251-262.
43. DE CLERCQ E: Suramin: a potent inhibitor of reverse transcriptase of RNA tumor viruses. Cancer Lett. (1979) 8:9-22.
44. SUTHERLAND IA, PEREGRINE AS, LONSDALE-ECCLES JD et al.: Transport of isometamidium (samorin) by drug resistant and drug-sensitive T. congolense. Parasitology (1991) 103:245-251
45. SUTHERLAND IA, MOUNSEY A, HOLMES PH: Reduced accumulation of isometamidium by drug resistant T. congolense. Parasitology (1992) 104:461-467.
46. MCCANN PP, PEGG AE: Ornithine decarboxylase as an enzyme target for therapy. Pharmacol. Ther. (1992) 54:195-215.
47. BARRET SV, BARRET MP: Anti-sleeping sickness drugs and cancer chemogtherapy. Parasitology Today (2000) 16:7-9.
48. PEPIN J, MILORD F: The treatment of human African trypanosomiasis. Adv. Parasitol. (1994) 33:1-47.
49. BITONTI AJ, BACCHI CJ, McCANN PP et al.: Uptake of difluoromethylornithine by Trypanosoma brucei brucei. Biochem. Pharmacol. (1986) 35:351-354.
50. PHILLIPS MA, WANG CC: Trypanosoma brucei brucei mutant resistant to α-difluoromethylornithine. Mol. Biochem. Parasitol. (1987) 22:9-17.
51. GHODA L, PHILPIPS MA, BASS KE et al.: Trypanosome ornithine decarboxylase is stable because it lacks sequences found in the carboxyl terminus of the mouse enzyme which target the latter for intracellular degradation. J. Biol. Chem (1990) 265:11823-11826.
52. ITEN M, METT H, EVANS A et al.: Alteration in ornithine decarboxylase characteristics accounts for tolerance of Trypanosoma brucei rhodesiense to D,L-difluoromethylornithine. Antimicrob. Agents Chemother. (1997) 41:1922-1925.
53. VAN NIEUWENHOE S, DECLERQ V: Nifurtimox therapy in late stage arsenical refractory gambiense sleping sickness in. Proceedings of 17th Meeting ISCTRC Arusha. OAU/STRC, Nairobi, Kenya (1989):264.
54. TOWNSON SM, BOREHAM PL, UPCROFT P et al.: Resistance to nitroheterocyclic drugs. Acta Trop. (1994) 56:125-141.
55. FAIRLAMB AH: Future prospects for the chemotherapy of human trypanosomiasis 1. Novel approaches to the chemotherapy of trypanosoiasis. Trans. R. Soc. Trop. Med. Hyg. (1990) 84:613-617.
56. FAIRLAMB AH: Trypanothione metabolism and rational approach to drug design. Biochem. Soc. Trans. (1990) 18:717-720.
57. DUHM B, MAUL W, MEDENWALD P: Investigations on Pharmacokinetics of nifurtimox- 35 S in rat and dog. Arzneimittelforschung (1972) 22:1617-1624.
58. VAN NIEUWENHOE S, DECLERQ J: Nifurtimox (lampit) treatment in late stage of gambiense sleeping sickness. In: Proceedings 17th Meeting ISCTRC Arusha. OAU/STRC, Nairobi, Kenya (1981):206.
59. VAN NIEUWENHOE S: Advances in sleeping sickness therapy (1992) 72:39-51.
60. MOENS F, DE WILDE M, NGATO K: Traitement au nifurtimox de la trypanossomiase humaine africaine. Ann. Soc. Belge. Med. Trop. (1984) 64:37-43.
61. MONTALTO D, MECCA M, DIAZ EG, CAATRO JA: Nifurtimox biotransformation to reactive metabolites or nitrites in liver fractions and odel systems. Toxicol. Lett. (2002) 15:1-8.
62. JENNINGS FW: Combination therapy of CNS trypanosomiasis. Acta Trop. (1993) 54:205-213.
63. ENANGA B, NDONG JM, BONDRA H et al.: Pharmacokinetics, metabolism and excreation of megazol in Tb gambiense primate model human African trypanosomiasis. Arzneimittelforschung (2000) 50:158-162.
64. KEISER J, BURRI C: Physicochemical properties of the trypanocidal drug melarsoprol. Acta Trop. (2000) 74:101-104.
65. ATAWODI SE, IBARHIM S, AMEH D et al.: Indigenous knowledge system for treatment of trypanosomiasis in kaduna state of Nigeria. J. Ethnopbarmacol. (2002) 79:279-282.
66. NOK AJ, ESIEVO KA, LONGDET I et al.: Trypanocidal potentials of Azadirachta indica: in vivo activity of leaf extract against Trypanosoma brucei. J. Clin. Biochem. Nutr. (1993)15:113-118.
67. NOK AJ, WILLIAMS S, ONYENEKWE PC: Allium sativa induced death of African trypanosomes. Parasitol. Res. (1996) 82:634-637.
68. NOK AJ: Azaanthraquinone inhibits respiration and in vitro growth of long slender bloodstream forms of Trypanosoma congolense. Cell Biochem. Func. (2001) 19:1-8.
69. FREIBURGHAUS F, OGWAL EN, NKUNYA MH et al.: In vitro antitrypanosomal activity of African plants used in traditional medicine in Uganda to treat sleeping sickness. Trap. Med. Int. Health (1996) 1(6):765-771.
70. ATINDEJOU KK, SCHMID C, BRUN R et al.: Antitrypanosomal and antiplasmodial activity of medicinal plants from Côte d'Ivoire. J. Ethnopharmacol. (2004) 90:221-227.
71. HONDA G, TABATA M: Isolation of antifungal principle tryptanthrin, from Strobilanthes cusia. Planta Med. (1979) 36:85-90.
72. SCOVILL J, BLANK E KONNICK M et al.: Antitrypanosomal activities of tryptanthrin. Antimicrob. Agents Chemother. (2002) 46:882-883
73. HAINES LR, HANCOCK RE, PEARSON TW: Cationic antimicrobial peptide killing of African trypanosomes and Sodalis glossinidius, a bacterial symbiont of the insect vector of sleeping sickness. Vectorborne Zoonotic Diseases (2003) 3:175-186.
74. LINGER M, ACOSTA-SERRANO A, VAN DEN ABBEELE J et al.: Cleavage of trypanosome surface glycoproteins by alkaline trypsin-like enzyme(s) in the mid gut of Glossina morsitans. Int. J. Parasitol. (2003) 33:1319-1328.